LeMaitre Vascular (NASDAQ: LMAT) saw its stock price plummet 5.81% in after-hours trading on Thursday following the release of its first-quarter 2025 financial results. The sharp decline came as the company's earnings fell short of analyst expectations, overshadowing a strong sales performance.

The vascular device manufacturer reported quarterly earnings of $0.48 per share, missing the analyst consensus estimate of $0.50 by 4 percent. This earnings miss appears to be the primary driver behind the stock's after-hours selloff, despite representing a 9.09 percent increase over earnings of $0.44 per share from the same period last year.

On a more positive note, LeMaitre Vascular's quarterly sales came in at $59.87 million, beating the analyst consensus estimate of $57.64 million by 3.87 percent. The company's top-line growth was impressive, showing an 11.95 percent increase over sales of $53.48 million in the same period last year. However, the strong sales performance was not enough to offset investor concerns about the earnings miss.

The market's negative reaction to LeMaitre's mixed results highlights the importance investors place on meeting or exceeding earnings expectations, even when other financial metrics show positive growth. As the company moves forward, it will likely face increased pressure to align its bottom-line performance with analyst projections while maintaining its strong sales momentum.